Mylan expands women's healthcare portfolio with Famy Care acquisition

PITTSBURGH and MUMBAI, India — Mylan announced that it will acquire certain businesses from specialty women's healthcare company Famy Care Limited for $750 million, with additional contingent payments of up to $50 million. 

 

Famy Care is a global leader in generic oral contaceptive products and its acquisition by Mylan makes it a leader in the hormonal contraceptives market, Mylan said. The transaction is expected to close in the second half of 2015. 

 

"In 2008, Mylan established a partnership with Famy Care, significantly enhancing its presence in the women's health care segment in the United States and other developed country markets. With today's acquisition, we are building on this successful partnership and further accelerating our global growth in this important therapeutic area," said Mylan CEO Heather Bresch.

 

The transaction will complement the company's pending acquisition of Abbot's non-U.S. developed markets specialty and branded generics business, which also contains a women's healthcare portfolio. 

 

"By adding this vertically integrated business and globalizing our women's healthcare platform, we are creating the right foundation to become a leader in this growing, attractive sector. Famy Care brings us a broad portfolio, strong technical capabilities and dedicated hormone manufacturing, which complement Mylan's powerful global commercial footprint and supply chain infrastructure," said Mylan president Rajiv Malik.